Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
StockNews.AI ยท 2 hours
AI Summary
Immunome announced the first patient dosing in the Phase 1 trial of IM-1617, a first-in-class solid-tumor ADC using the HC74 TOP1 payload. The company also outlined IND timing for IM-1340 and IM-1335 in mid- and late-2026, signaling continued ADC pipeline momentum and potential near-term catalysts for IMNM if early results are favorable.
Sentiment Rationale
Phase 1 dosing milestone and near-term IND timelines typically provide positive sentiment for clinical-stage names; potential re-rating if early signals look favorable, similar to prior ADC program milestones in small-cap biotech peers.
Trading Thesis
Bullish into 2026 as IM-1617 progresses and IND timing for IM-1340/IM-1335 approaches.
Market-Moving
- First patient dosed in IM-1617 Phase 1 could trigger near-term upside.
- IND timing for IM-1340/IM-1335 in 2026 may re-rate the stock.
- HC74 TOP1 payload differentiation may lift valuation of Immunome's ADC platform.
Key Facts
- IM-1617 dosed in Phase 1; first-in-human solid-tumor ADC with HC74 payload.
- IND submissions for IM-1340 and IM-1335 planned for mid-2026 and late-2026.
- IM-1617 targets an undisclosed RTK; preclinical data show tumor regression.
- Phase 1 will include colorectal cancer, NSCLC, and breast cancer.
- HC74 payload is Immunome's TOP1 inhibitor used in ADCs.
Companies Mentioned
- Immunome, Inc. (IMNM): Dosed first patient in IM-1617 Phase 1; INDs for IM-1340/IM-1335 planned; ADC platform momentum.
- Business Wire: Source of press release; not an investable company.
- N/A (N/A): No other public company names tied to the reported catalysts.
Corporate Developments
Category: Corporate Developments. The item describes stage progress and near-term catalysts in Immunome's ADC pipeline, aligning with corporate-venture risk/reward dynamics rather than quarterly earnings signals.